Patients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study - 14/04/20
Funding sources: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. |
|
Conflicts of interest: Dr Huilaja has received educational grants from CSL Behring, Shire, Janssen-Cilag, Novartis, AbbVie, and LEO Pharma; honoraria from Novartis, Sanofi Genzyme, and UCB Pharma for consulting and/or speaking; and is an investigator for AbbVie. Dr Lipitsä has received educational grants from AbbVie and is an investigator for AbbVie. Dr Harvima has received educational grants from AbbVie. Dr Vihervaara has received educational grants from AbbVie, Jansen, Novartis, and Celgene. Dr Pasternack has received educational grants from AbbVie, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi Genzyme; honoraria from AbbVie, Galenica, Eli Lilly, Janssen, Novartis, and Sanofi Genzyme for consulting and/or speaking; participated in clinical studies sponsored by AbbVie, Novartis, Eli Lilly, and Regeneron, and is an investigator for AbbVie. Dr Kouri has received educational grants from Pfizer. Authors Ranta and Hirvonen are employees of AbbVie and may or may not own AbbVie stock. Author Sintonen has no conflicts of interest. |
|
IRB approval status: The Tampere University Hospital Ethics Committee approved this study (R16017/2016). |
|
Reprints not available from the authors. |
Vol 82 - N° 5
P. 1232-1234 - mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?